The MAP3K10 antibody targets mitogen-activated protein kinase kinase kinase 10 (MAP3K10), a serine/threonine kinase within the MAPK signaling pathway, which regulates cellular responses like proliferation, differentiation, and stress. Also known as MLK2 or MST, MAP3K10 activates downstream kinases (e.g., JNK, p38) through phosphorylation cascades. Structurally, it contains SH3 and leucine zipper domains, facilitating protein-protein interactions critical for signaling.
MAP3K10 is implicated in neuronal development, influencing axon guidance and synaptic plasticity. Dysregulation links it to pathologies: overexpression or mutations are observed in cancers (e.g., hepatocellular carcinoma, neuroblastoma), where it may act as an oncogene or tumor suppressor depending on context. Its role in apoptosis and inflammation also ties it to neurodegenerative and metabolic disorders.
Antibodies against MAP3K10 are vital tools for studying its expression, activation, and interactions. They enable detection via Western blot, immunohistochemistry, or immunofluorescence, helping elucidate its function in disease models or signaling networks. Some antibodies specifically recognize phosphorylated forms, aiding in pathway activity analysis. Commercial variants vary in clonality (monoclonal/polyclonal), species reactivity, and applications, necessitating validation for experimental conditions. Research using these antibodies has advanced understanding of MAP3K10's dual roles in health and disease, highlighting its therapeutic potential.